In this regard, the results of the recent RV144 trial suggest that IgG antibodies targeting V1/V2 gp120 region may have contributed to protection against HIV-1 infection, whereas high levels of Env-specific IgA antibodies in serum may have mitigated the effects of protective antibodies [39,97]. The gene discussed is ERVW-1; the disease is HIV-1 infection.